Escalating Temporary Gastric Electrical Stimulation (GES) for Severe Gastroparesis
NCT ID: NCT02164591
Last Updated: 2020-08-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
19 participants
OBSERVATIONAL
2013-02-28
2019-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Multi-Channel Gastric Electrical Stimulation for the Treatment of Gastroparesis
NCT00595621
Temporary Gastric Electrical Stimulation for Gastroparesis
NCT01054794
Temporary Gastric Electrical Stimulation for Drug Refractory Gastroparesis
NCT00432835
Gastric Electrical Stimulation (GES) and Pyloroplasty for the Treatment of Gastroparesis
NCT03123809
Gastric Pacemaker Implantation for Gastroparesis
NCT00568373
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Solid phase 4-hr gastric scintigraphy is consistent with gastroparesis within 3 months of study enrollment\*
* retention at 2 hr: \>60% or
* retention at 4 hr: \>10% \*Based on International consensus on gastric scintigraphy
Exclusion Criteria
* Small bowel malrotation
* Inflammatory bowel disease
* Contraindication for surgical implantation of GES
* Presence of illness that may require MRI during the study; such as pituitary tumor, herniated disc, spinal stenosis, multiple sclerosis, etc.
* Significant comorbidity due to sever cardiovascular, renal, pulmonary, or liver disease.
* Significant coagulopathy
* Non-ambulatory patients: bed-ridden, nursing home resident, etc.
* Pregnancy
* Unable to give own informed consent
* Prisoners
18 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Indiana University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
John M. Wo
MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
John M Wo, MD
Role: PRINCIPAL_INVESTIGATOR
Indiana University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Indiana University Hosptial
Indianapolis, Indiana, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Temp GES
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.